To receive board certification in neurosurgery, candidates must complete seven years of residency training and an optional one- or two-year fellowship. Following residency, candidates complete several years practicing medicine, in which they are to log 125 cases prior to a rigorous oral and written examination.
Read Press ReleaseMovement data intelligence company Blyncsy joins Newlab - a community of experts and innovators applying transformative technology to solve the worldʼs biggest challenges - with the New York City Department of Transportation.
Read Press ReleaseThe National Certification Board for Behavioral Health Professionals (NCBBHP) announced that going forward Mental Health America's (MHA) National Certified Peer Specialist (NCPS) program will be consolidated and managed by NCBBHP.
Read Press ReleaseMedtech, Biotech, and Pharma industries will gather for the Medtech A+ Team - how to do a successful RegA+ for a Medtech company in a different format, with quicker panels and more information
Read Press ReleaseTen hand-selected teams will participate in their second annual Care Economy & Family Technology Academy combining a customized advisory, expert-led content, and industry exposure to emerging caregiving support solutions.
Read Press ReleaseHigh-growth diabetes company Diabeloop closes its Series C financing round - led by LBO France, joined by Terumo Corporation, Innovacom and backed by Diabeloop's historical partners - to power the company's commercial roll-out and global expansion.
Read Press ReleaseOver 900 hospitals and inpatient organizations and 4,000 physician practices were represented in the sweeping Q1-Q2 2022 series of financial management IT user polls, as daunting challenges are forcing providers to advance their technologies to maintain solvency.
Read Press ReleaseBlack Book Research estimates the North American market for post-acute software and IT services market in Q2 2022 has reached $3.0 Billion and is anticipated to grow at a CAGR of 17% during 2022-2032.
Read Press ReleaseRecardio Inc., a late stage clinical-stage life science company developing regenerative therapies for cardiovascular diseases, announced that the FDA concurs with Recardio's pivotal Heal-MI Phase 3 trial design with Dutogliptin in Acute Myocardial Infarction.
Read Press Release● Flagman Founder Cindy Iodice Holds Press Conference June 2, Scheduled After Historic Sentencing in Slow Down Move Over (SDMO) Case ● U.S. Senator Richard Blumenthal Joins to Discuss Congressional Efforts to Promote Road Safety
Read Press Release